• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to secondary sidebar

OINDPnews


H&T Presspart Low GWP Banner
  • Home
  • News
    • Business
    • Features
    • Medical
    • Regulatory
    • Products and Services
    • People
  • Events
  • Suppliers
    • Supplier listing and advertising options
    • Capsules and blisters
    • Consultants
    • Contract research
    • Contract manufacturing
    • Devices
    • Education
    • Excipients
      • Clinical Technology
    • Filling equipment
    • Instruments
    • Particle manufacturing
    • Software and modeling
  • Jobs
  • Resources
    • Webinars
    • White papers
  • LGWP Propellants
    • HFA 152a
    • HFO-1234ze(E)
    • LGWP Regulation
  • Contact

News

Grifols licenses Aradigm’s inhaled ciprofloxacin formulations

Grifols is paying $25 million upfront, plus up to $25 million in milestone payments to acquire a worldwide license for Aradigm’s Pulmaquin and Lipoquin inhaled ciprofloxacin formulations. Grifols will also pay tiered royalties on worldwide sales of products using the formulations and will be responsible for up to $65 million in expenses for Phase 3 development and … [Read more...] about Grifols licenses Aradigm’s inhaled ciprofloxacin formulations

Malvern and Proveris team on spray characterization system

Malvern Instruments has announced that it will team up with Proveris Scientific Corporation on a nasal spray characterization system called Solo for Spraytec, which combines Proveris's automated actuator and software for precise control of device actuation with Malvern's Spraytec laser diffraction particle size analyzer. The FDA recommends laser diffraction for … [Read more...] about Malvern and Proveris team on spray characterization system

Vectura announces reduced losses, new CFO

Inhaled drug developer Vectura has announced better than expected preliminary results for the year ending March 31, 2013, with the company's loss before tax 21% lower than in 2011/12. The company also announced that Paul Oliver will replace Anne Hyland as CFO. Vectura CEO Chris Blackwell said, “The past year has been very significant for Vectura, driven by the … [Read more...] about Vectura announces reduced losses, new CFO

Safety studies show no increased risk with use of Brovana inhalation solution

According to Sunovion Pharmaceuticals, data from a year-long clinical trial comparing the safety of Brovana arformoterol tartrate inhalation solution versus placebo in patients with moderate-to-severe COPD show no increased risk of exacerbations or death due to a respiratory event. Fewer than 10% of patients treated with 15 mcg of Brovana twice daily had serious … [Read more...] about Safety studies show no increased risk with use of Brovana inhalation solution

Pearl Therapeutics initiates Phase 3 program for LAMA/LABA MDI

Pearl Therapeutics has announced the initiation of a Phase 3 program called PINNACLE for its PT003 glycopyrrolate/formoterol fumarate metered dose inhaler for patients with moderate-to-severe COPD. The program will include two studies involving more than 2,700 patients in North America, Europe, Australia, and New Zealand. Enrollment is expected to be complete by … [Read more...] about Pearl Therapeutics initiates Phase 3 program for LAMA/LABA MDI

Aegis gets second patent for intranasal formulations of triptans

According to Aegis Therapeutics, the company has been granted US Patent No. 8,440,631 for fast-acting formulations of triptans for the treatment of migraines. The patent is the second for Aegis's triptan nasal sprays using its Intravail transmucosal absorption enhancers; the company got the first patent in September 2012. Clinical trials have demonstrated that … [Read more...] about Aegis gets second patent for intranasal formulations of triptans

Insmed gets European patent for Arikace

The European Patent Office will grant Insmed Incorporated EU Patent No. 1909759 for Arikace liposomal amikacin for inhalation, according to Insmed. The composition of matter patent, titled "Sustained release of anti-infective aminoglycosides," covers formulations of aminoglycosides, including amikacin, with Insmed's liposomal delivery platform, formulation methods, … [Read more...] about Insmed gets European patent for Arikace

Elan makes billion dollar deal for inhaled drug royalites

Elan Corporation has announced that it will pay Theravance $1 billion for a 21% participation interest in future royalty payments from sales of Breo (Relvar) Ellipta, Anoro Ellipta, MABA '081 bifunctional muscarinic antagonist-beta2 agonist monotherapy, and vilanterol monotherapy. Elan CEO Kelly Martin explained, “This transaction, upon closing, will immediately … [Read more...] about Elan makes billion dollar deal for inhaled drug royalites

New joint venture in China to develop inhaled drugs

Vectura has announced that it has partnered with Chinese pharmaceutical company Tianjin KingYork Group and Hong Kong private equity investor Zendex Bio Strategy to create Tianjin Kinnovata Pharmaceutical Company Limited ("Kinnovata"). The new company will develop, manufacture, and market inhaled drugs for asthma and COPD in Asia. Kinnovata will be an independent … [Read more...] about New joint venture in China to develop inhaled drugs

FDA approves Breo Ellipta

The FDA has approved GSK and Theravance's Breo Ellipta fluticasone furoate/vilanterol inhalation powder for the treatment of COPD). The FDA’s Pulmonary-Allergy Drugs Advisory Committee (PADAC) voted to recommend approval of Breo Ellipta in April 2013. Theravance will make a $30 million milestone payment to GSK following the approval. The FDA notes that, "The drug … [Read more...] about FDA approves Breo Ellipta

  • « Previous Page
  • Page 1
  • Interim pages omitted …
  • Page 339
  • Page 340
  • Page 341
  • Page 342
  • Page 343
  • Interim pages omitted …
  • Page 416
  • Next Page »

Primary Sidebar

Sign up for our free weekly newsletter

Upcoming Events
Sponsored by Intertek

Want information about upcoming OINDP-related events delivered directly to your inbox? click here

  • June 17-June 18: Rescon Europe 2025, Paris, France
  • June 19-June 20: Metered Dose Inhaler (MDI) Technology Training Course, online
  • June 22-June 25: ISAM Congress 2025, Washington, DC, USA
  • June 25-June 25: SMI.London 2025, London, UK
  • September 18-September 19: IPAC-RS Nasal Innovation Forum, West Trenton, NJ, USA
  • See all upcoming events

    Secondary Sidebar

    Suppliers

    Capsules and blisters
    Consultants
    Contract research
    Contract manufacturing
    Devices
    Education
    Excipients
    Filling equipment
    Instruments
    Particle manufacturing
    Software and modeling
    Intertek banner
    Bespak Leading the Green Transition banner
    © 2025 OINDPnews